Management of Bladder Cancer following Solid Organ Transplantation

Table 1

Characteristics of patients with nonmuscle-invasive TCC of the bladder.

Patient number	1, 2	3	4	5	6	7
Age at transplant	66	77	82	66	63	45
Type of transplant	Liver	Renal	Renal	Renal	Liver	Renal
Age at diagnosis	66	79	83	72	65	47
Immunosuppression	FK, MMF, Pred	FK, Pred	FK	FK, MMF	FK, Pred	FK, Pred
Clinical stage	T1NxMx	T1NxMx	TisNxMx	TisNxMx	TisNxMx	T1N0Mx
Histology	TCC	TCC	CIS	CIS	CIS	TCC
Grade	Low	Low	High	High	High	High
Treatment	TURBT	TURBT	TURBT	TURBT	TURBT	Cystectomy, ureteroureterostomy
Adjuvant therapy	None	BCG	BCG	BCG	BCG	Mitomycin C
Followup (months)	28, 24	40	36	84	42	98
Recurrence	None	Local	Local	None	Local	None

FK: tacrolimus; MMF: mycophenolate mofetil; Pred: prednisone; CIS: carcinoma in site; TURBT: transurethral resection bladder tumor; BCG: bacille-Calmette Guerin.